Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy
| Autor: | Dawn J Storey, L C Frew, Duncan B. McLaren, M A Atkinson, Isabella Butcher, Michael Sharpe, John F. Smyth |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Neoplasms Hormone-Dependent Antineoplastic Agents Hormonal Urology Population Pain Anxiety lcsh:RC870-923 Hospital Anxiety and Depression Scale Gonadotropin-Releasing Hormone Androgen deprivation therapy Prostate cancer Internal medicine Prevalence medicine Humans Brief Pain Inventory education Fatigue Depression (differential diagnoses) Aged Aged 80 and over education.field_of_study Depression business.industry Prostatic Neoplasms Hematology Odds ratio Middle Aged lcsh:Diseases of the genitourinary system. Urology medicine.disease Cross-Sectional Studies Logistic Models Oncology Multivariate Analysis Quality of Life Physical therapy International Prostate Symptom Score Self Report medicine.symptom business |
| Zdroj: | International braz j urol, Volume: 37, Issue: 6, Pages: 798-799, Published: DEC 2011 International Brazilian Journal of Urology, Vol 37, Iss 6, Pp 798-799 (2011) |
| Popis: | Background: The purpose of the study was to determine the prevalence and associations of clinically relevant fatigue (CRF) in men with biochemically controlled prostate cancer on long-term androgen deprivation therapy (ADT). Patients and methods: One hundred and ninety-eight men were surveyed and the prevalence of CRF (Brief Fatigue Inventory score >3) determined. Associations with other measures (Hospital Anxiety and Depression Scale; International Prostate Symptom Score; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Brief Pain Inventory worst pain; clinical and demographic information) were explored in univariate and multivariate analyses. Results: Eight-one per cent (160 of 198) of questionnaires were analysable. CRF prevalence was 43% (68 of 160). CRF associations included moderate/severe urinary symptoms, anxiety and medical co-morbidities; the strongest associations were depression [odds ratio (OR) 9.8, 95% confidence interval (CI) 4.3-22.8] and pain (OR 9.2, 95% CI 4.0-21.5). After controlling for other factors, the independent associations were depression (OR 4.7, 95% CI 1.6-14.0) and pain (OR 3.1, 95% CI 1.0-8.9). There was no association with age, disease burden or treatment duration. Conclusions: Two-fifths of men with biochemically controlled prostate cancer on long-term ADT report CRF that interferes with function. Management aimed at improving CRF should address depression and pain. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|